VRCA Verrica Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRCA

Price (delayed)

$4.62

Market cap

$79.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.75

Enterprise value

$69.98M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the ...

Highlights
The equity has surged by 125% year-on-year but it has dropped by 73% since the previous quarter
The revenue has surged by 106% year-on-year but it has declined by 18% since the previous quarter
The quick ratio has decreased by 43% from the previous quarter and by 12% YoY
The gross margin has decreased by 4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.verrica.com
Peers: OPK ORGO

Key stats

What are the main financial stats of VRCA

VRCA stock price

How has the Verrica Pharmaceuticals stock price performed over time
Intraday
-2.12%
1 week
1.99%
1 month
-4.15%
1 year
7.19%
YTD
-44.4%
QTD
-24.51%

Financial performance

How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$30.32M
Gross profit
$26.04M
Operating income
-$28.38M
Net income
-$31.18M
Gross margin
85.9%
Net margin
-102.8%
Verrica Pharmaceuticals's operating margin has plunged by 152% from the previous quarter but it has soared by 64% YoY
VRCA's net margin has shrunk by 114% QoQ but it has soared by 69% YoY
The revenue has surged by 106% year-on-year but it has declined by 18% since the previous quarter
VRCA's operating income has dropped by 106% since the previous quarter but it is up by 27% year-on-year

Price vs fundamentals

How does VRCA's price correlate with its fundamentals

Growth

What is Verrica Pharmaceuticals's growth rate over time

Valuation

What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
18.43
P/S
3.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.31
The EPS has soared by 77% year-on-year but it has dropped by 58% since the previous quarter
The equity has surged by 125% year-on-year but it has dropped by 73% since the previous quarter
The revenue has surged by 106% year-on-year but it has declined by 18% since the previous quarter
The stock's price to sales (P/S) is 93% less than its 5-year quarterly average of 47.2 but 19% more than its last 4 quarters average of 2.8

Efficiency

How efficient is Verrica Pharmaceuticals business performance
The ROS has dropped by 178% since the previous quarter but it has soared by 66% year-on-year
The return on invested capital has dropped by 128% year-on-year
The return on assets has dropped by 78% since the previous quarter but it has grown by 34% year-on-year
The ROE has soared by 61% from the previous quarter

Dividends

What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRCA.

Financial health

How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 14% higher than its total liabilities
Verrica Pharmaceuticals's total liabilities has decreased by 44% YoY but it has increased by 40% from the previous quarter
The quick ratio has decreased by 43% from the previous quarter and by 12% YoY
VRCA's debt is 58% lower than its equity
The equity has surged by 125% year-on-year but it has dropped by 73% since the previous quarter
Verrica Pharmaceuticals's debt to equity has soared by 119% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.